Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 32.29%.

  • Theravance Biopharma's EBIT Margin rose 319500.0% to 32.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.85%, marking a year-over-year increase of 287600.0%. This contributed to the annual value of 72.92% for FY2024, which is 246600.0% up from last year.
  • As of Q3 2025, Theravance Biopharma's EBIT Margin stood at 32.29%, which was up 319500.0% from 10.4% recorded in Q2 2025.
  • Theravance Biopharma's 5-year EBIT Margin high stood at 10.4% for Q2 2025, and its period low was 1540.08% during Q1 2022.
  • In the last 5 years, Theravance Biopharma's EBIT Margin had a median value of 110.16% in 2024 and averaged 248.83%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 42433100bps in 2021, then tumbled by -9516500bps in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's EBIT Margin stood at 375.8% in 2021, then skyrocketed by 68bps to 119.0% in 2022, then soared by 70bps to 35.53% in 2023, then tumbled by -38bps to 49.06% in 2024, then skyrocketed by 34bps to 32.29% in 2025.
  • Its EBIT Margin stands at 32.29% for Q3 2025, versus 10.4% for Q2 2025 and 93.8% for Q1 2025.